NewAmsterdam Pharma Company N.V. (NAMS) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 15, 2026
Current Price
$35.44
Price Target
$46.00
Target Range
$37.00 — $55.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-20.3x
Forward PEG—
Implied Growth-2.8%
Median Target$46.00
Analyst Spread39.1%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$37
+4.4%
Consensus
$46
+29.8%
Bull Case
$55
+55.2%
NAMS Price Target Analysis
Updated May 16, 2026As of May 16, 2026, NewAmsterdam Pharma Company N.V. (NAMS) has a Wall Street consensus price target of $46.00, based on estimates from 10 covering analysts. With the stock currently trading at $35.44, this represents a potential upside of +29.8%. The company has a market capitalization of $4.14B.
Analyst price targets range from a low of $37.00 to a high of $55.00, representing a 39% spread in expectations. The median target of $46.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NAMS trades at a trailing P/E of -20.3x. Analysts expect EPS to grow -2.8% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+14.9%
Avg Forward P/E15.7x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ESPREsperion Therapeutics, Inc. | $649M | $3.12 | $3.19 | +2.2% | Hold | — | 25 |
 MDGLMadrigal Pharmaceuticals, Inc. | $12.1B | $523.69 | $712.00 | +36.0% | Buy | — | 23 |
 LNTHLantheus Holdings, Inc. | $6.1B | $93.91 | $103.50 | +10.2% | Buy | 17.6x | 17 |
 PFEPfizer Inc. | $144.1B | $25.33 | $27.60 | +9.0% | Hold | 8.5x | 39 |
 MRKMerck & Co., Inc. | $275.1B | $111.38 | $129.31 | +16.1% | Buy | 21.7x | 37 |
 NVSNovartis AG | $282.6B | $148.08 | $141.00 | -4.8% | Hold | 16.9x | 25 |
 AZNAstraZeneca PLC | $281.5B | $181.58 | $211.00 | +16.2% | Buy | 17.7x | 41 |
 AMGNAmgen Inc. | $176.1B | $326.31 | $352.00 | +7.9% | Buy | 14.6x | 38 |
 REGNRegeneron Pharmaceuticals, Inc. | $72.6B | $698.25 | $865.68 | +24.0% | Buy | 15.1x | 48 |
 IQVIQVIA Holdings Inc. | $28.7B | $169.12 | $223.75 | +32.3% | Buy | 13.2x | 44 |
Upside Potential Comparison
MDGLIQVREGNAZNMRKLNTHPFEAMGNSee NAMS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NAMS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NAMS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNAMS — Frequently Asked Questions
Quick answers to the most common questions about buying NAMS stock.
What is the NAMS stock price target for 2026?
The consensus Wall Street price target for NAMS is $46, representing 29.8% upside from the current price of $35.44. With 10 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is NAMS a buy, sell, or hold?
NAMS has a consensus rating of "Buy" based on 10 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $46 implies 29.8% upside from current levels.
Is NAMS stock overvalued or undervalued?
NAMS's current price is $35.44 with a consensus target of $46 (29.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can NAMS stock go?
The most bullish Wall Street analyst has a price target of $55 for NAMS, while the most conservative target is $37. The consensus of $46 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover NAMS stock?
NAMS is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the NAMS stock forecast?
The 12-month NAMS stock forecast based on 10 Wall Street analysts shows a consensus price target of $46, with estimates ranging from $37 (bear case) to $55 (bull case). The median consensus rating is "Buy".
Should I buy NAMS stock?
Wall Street analysts are very optimistic on NAMS, with a "Buy" consensus rating and $46 price target (29.8% upside). 9 of 10 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do NAMS price targets vary so much?
NAMS analyst price targets range from $37 to $55, a 39% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $46 consensus represents the middle ground.